65 results for “transfer pricing”+ Section 37clear
Sorted by relevance
Key Topics
Showing 1–20 of 65 · Page 1 of 4
Bench: HON'BLE THE CHIEF JUSTICE
37 on 13.02.2022. The report states, inter alia, that: “More 600 brand name drugs were dispensed and paid for by Part D plans in 2016, despite the presence of generic competition. Plans and beneficiaries paid $8.7 billion for multiple source brands and $34.0 billion for generics. Full substitution of multiple source brands would have resulted in total spending on generic